Eterna Therapeutics Inc
$ 4.39
-3.09%
11 Aug - close price
- Market Cap 5,120,200 USD
- Current Price $ 4.39
- High / Low $ 4.72 / 4.23
- Stock P/E N/A
- Book Value 5.88
- EPS -5.19
- Next Earning Report 2026-08-12
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.81 %
- ROE -25.06 %
- 52 Week High 48.00
- 52 Week Low 3.18
About
Brooklyn ImmunoTherapeutics, Inc., a clinical-stage biopharmaceutical company, is dedicated to developing therapies to treat cancer patients. The company is headquartered in Brooklyn, New York.
Analyst Target Price
$30.00
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-11 | 2026-03-13 | 2025-11-07 | 2025-08-13 | 2025-05-07 | 2025-03-13 | 2024-11-12 | 2024-08-13 | 2024-05-13 | 2024-03-13 | 2023-11-13 | 2023-08-11 |
| Reported EPS | -6.95 | -4.8065 | -0.15 | -0.61 | -2.31 | -0.15 | -1844.085 | -383.8031 | -460.744 | -427.0564 | -1.0335 | -0.8516 |
| Estimated EPS | -1.95 | None | 0 | 0 | 0 | 0 | None | None | None | None | None | None |
| Surprise | -5 | 0 | -0.15 | -0.61 | -2.31 | -0.15 | 0 | 0 | 0 | 0 | 0 | 0 |
| Surprise Percentage | -256.4103% | None% | None% | None% | None% | None% | None% | None% | None% | None% | None% | None% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-12 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -3.3 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ERNA
2026-08-10 12:42:14
Ernexa Therapeutics has appointed David Polinsky, a veteran biotech executive with over 25 years of experience, to its Board of Directors. This move comes as the company prepares to submit an Investigational New Drug (IND) application for its lead cell therapy program, ERNA-101, in Q3 2026 and initiate its first Phase 1 clinical study in Q4 2026. Polinsky's expertise in oncology, capital markets, M&A, and corporate governance is expected to strengthen Ernexa's leadership during its transition to a clinical-stage company.
2026-08-08 00:12:15
Ernexa Therapeutics Inc is anticipated to report a loss of $3.84 per share, according to an earnings preview. This information is sourced from Refinitiv via Reuters. The full article can be accessed on TradingView, which provides market data and news.
2026-08-04 09:40:40
This article provides a brief mention of the "Price to sales forward" metric for Ernexa Therapeutics Inc. (NASDAQ: ERNA). The content is primarily a navigation and platform overview for TradingView, indicating that the detailed financial data would be found within their platform for the specified stock.
2026-08-04 07:41:42
This page provides financial information for Ernexa Therapeutics Inc. (NASDAQ: ERNA), specifically focusing on its forward price-to-earnings ratio. The content is part of a larger financial data and trading platform, TradingView, offering various tools and resources for market analysis.
2026-08-01 10:40:40
This article provides financial information for Ernexa Therapeutics Inc. (NASDAQ: ERNA) on TradingView. It indicates that the content is related to the company's revenue breakdown and financial performance, suggesting a focus on fundamentals and statistics. The article is primarily a navigation hub to financial data, rather than an analytical piece.
2026-07-28 23:40:40
Ernexa Therapeutics released a CEO Corner series installment where CEO Sanjeev Luther discussed how their novel cell therapy, ERNA-101, could revolutionize cancer treatment by enhancing existing immunotherapies. ERNA-101 is designed to transform immunologically "cold" tumors into targets for the immune system, particularly benefiting combination approaches. The company is advancing towards an IND submission in Q3 2026 and plans for a Phase 1 clinical study in Q4 2026, initially focusing on platinum-resistant ovarian cancer.
